Regen-cov and Ronapreve Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to global spread of COVID-19 infections, emergency authorization of antibody therapies, expansion of hospital infusion infrastructure, large-scale government procurement programs, rapid development of antiviral biologics.

The growth in the forecast period can be attributed to increasing focus on pandemic preparedness, rising demand for rapid-response biologics, expansion of outpatient infusion services, growing investment in monoclonal antibody platforms, increasing development of variant-specific therapies. Major trends in the forecast period include increasing deployment of monoclonal antibody therapies, rising use of passive immunization treatments, growing focus on early viral neutralization, expansion of emergency use biologics, enhanced integration of pandemic response therapies.

The rising incidence of infectious diseases is expected to drive the growth of the regen-cov and ronapreve market going forward. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which spread through contact, air, water, or contaminated food. The increase in infectious diseases is fueled by factors like climate change, which expands the range of vectors such as mosquitoes, and globalization, which facilitates rapid spread of pathogens across borders. Regen-Cov (Ronapreve) is a monoclonal antibody cocktail used to treat COVID-19, targeting the SARS-CoV-2 virus to prevent severe illness, particularly in high-risk patients. For instance, in November 2024, according to the National Library of Medicine (NLM), a US-based government agency, between 5 and 11 November, 167,369 people in England tested positive for COVID-19, an 11% increase from the previous week, with the positivity rate remaining steady at 9.6%, close to the 9.7% reported the week before. Therefore, the rising incidence of infectious diseases is driving the growth of the regen-cov and ronapreve market.

The rising prevalence of chronic diseases is expected to support the growth of the regen-cov and ronapreve market going forward. Chronic diseases are long-term medical conditions that persist for a year or more, often requiring continuous management, such as diabetes, heart disease, and asthma. The growing prevalence of chronic diseases is driven by factors like aging populations, unhealthy lifestyles including poor diet and lack of exercise, and higher rates of risk factors such as obesity, diabetes, and hypertension. Regen-Cov and Ronapreve help patients with chronic diseases by reducing the risk of severe COVID-19 complications, offering targeted antibody protection for individuals with weakened immune systems. For instance, in July 2024, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based government health statistics agency, chronic conditions accounted for 78% of the fatal burden, an increase compared to previous years. Therefore, the rising prevalence of chronic diseases is driving the growth of the regen-cov and ronapreve market.

The rise in healthcare investments is expected to propel the growth of the regen-cov and ronapreve market going forward. Healthcare investments refer to the allocation of capital into the healthcare sector, including funding for medical technologies, pharmaceuticals, healthcare facilities, and services. The increase in healthcare investments is driven by factors such as an aging population, which raises demand for healthcare services, and advancements in medical technology that drive innovation and improve patient care. These investments support Regen-Cov and Ronapreve by funding clinical trials, expanding production, securing regulatory approvals, and enhancing distribution to ensure wider accessibility and adoption. For instance, in November 2025, according to the Organisation for Economic Co-operation and Development (OECD), a France-based intergovernmental organization, average health spending in OECD countries in 2024 was nearly USD 6,000 per capita, adjusted for differences in purchasing power. Therefore, the rising healthcare investments are driving the growth of the regen-cov and ronapreve market.

Major companies operating in the regen-cov and ronapreve market are F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals.

North America was the largest region in the regen-cov and ronapreve market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the regen-cov and ronapreve market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the regen-cov and ronapreve market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the regen-cov and ronapreve market by increasing costs associated with imported monoclonal antibody ingredients, bioreactor equipment, sterile fill-finish components, and cold-chain distribution infrastructure. Healthcare systems in North America and Europe are most affected due to reliance on global biologics manufacturing networks, while Asia-Pacific faces cost pressures linked to import-dependent supply. These tariffs are contributing to higher treatment delivery costs and logistical complexity. However, they are also accelerating regional biologics manufacturing investments, local fill-finish capacity expansion, and diversification of therapeutic supply chains.

The regen-cov and ronapreve market research report is one of a series of new reports that provides regen-cov and ronapreve market statistics, including regen-cov and ronapreve industry global market size, regional shares, competitors with a regen-cov and ronapreve market share, detailed regen-cov and ronapreve market segments, market trends and opportunities, and any further data you may need to thrive in the regen-cov and ronapreve industry. This regen-cov and ronapreve market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Regen-Cov and Ronapreve are monoclonal antibody therapies combining casirivimab and imdevimab, designed to neutralize SARS-CoV-2 by targeting its spike protein and preventing viral entry into cells. They are authorized for treating mild-to-moderate COVID-19 in high-risk patients and for post-exposure prophylaxis, effectively reducing hospitalization and mortality rates.

The primary clinical indications for Regen-Cov and Ronapreve include treatment of mild-to-moderate COVID-19, post-exposure prophylaxis (PEP), and pre-exposure prophylaxis (PrEP). Treatment of mild-to-moderate COVID-19 involves the use of medications for patients with COVID-19 who have mild to moderate symptoms and are not hospitalized. These therapies are distributed through hospitals, outpatient clinics, and home healthcare services, serving pediatric, adult, and geriatric patients.

The regen-cov and ronapreve market consists of sales of monoclonal antibodies, intravenous (IV) infusion solutions, and subcutaneous (SubQ) injection solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.